Systemic Treatments for Esophagogastric and Pancreas Cancer in the Adjuvant and Metastatic Settings
|
|
- Marcia Allison
- 5 years ago
- Views:
Transcription
1 Systemic Treatments for Esophagogastric and Pancreas Cancer in the Adjuvant and Metastatic Settings Peter C. Enzinger, MD Dana-Farber Cancer Institute & Harvard Medical School 2017 Master Class Course
2 Localized Esophageal Cancer What Can Surgery Accomplish?
3 Localized Esophageal Cancer Treated With Surgery Rice, Blackstone, Rusch. Ann Surg Oncol 2010
4 Localized Esophageal Cancer Does (Neo)Adjuvant Chemotherapy Improve Surgical Outcomes?
5 Neoadjuvant Chemotherapy Compared with Surgery Alone for Localized Esophageal Cancer Sjoquist et al. Lancet Oncol 2011;12(7):681-92
6 Localized Esophageal Cancer Does Neoadjuvant Chemoradiation Therapy Improve Surgery Outcomes?
7 All-Cause Mortality Estimates for Neoadjuvant C/RT Compared with Surgery Alone Sjoquist et al. Lancet Oncol 2011; 12(7):681-92
8 CROSS Study: Schema Chemoradiotherapy regimen: Paclitaxel 50mg/m 2 + Carboplatin AUC=2 on days 1, 8, 15, 22 and 29 Concurrent radiotherapy of 41.4 Gy in 23 fractions of 1.8 Gy Surgery within 6 weeks after completion of chemoradiotherapy (THE/TTE) Van Hagen et al. N Engl J Med 2012;366:
9 CROSS Study: Overall survival HR, 0.657; 95% CI mo 49.4 mo Van Hagen et al. N Engl J Med 2012;366:
10 POET: Schema Arm A PLF I PLF II PLF III (3 weeks) Surgery Week PLF I PLF II 15 x 2 Gy in 3 weeks Surgery Arm B PE (1 week) PLF: Cisplatin 50mg/m 2, 1h, d 1,15,29. Leukovorin/5-FU 500mg/m 2 2h / 2g/m2 24h, d1,8,15,22,29,36 PE: Cisplatin 50 mg/m 2, 1h, d 2+8. Etoposide 80 mg/m 2, 1h, d 3-5 Stahl M, et al. J Clin Oncol.2009;27:
11 POET: Overall Survival Arm A Arm B 47.4% 27.7% Log rank P = 0.07 HR Arm B vs A 0.67; 95% CI, ) Arm A Arm B Median survival 21.1 mo 33.1 mo Median follow-up 45.2 mo 46.2 mo Stahl M, et al. J Clin Oncol.2009;27:
12 Localized Esophageal Cancer Can Surgery Improve the Outcome of Chemoradiation?
13 Prospective Randomized Intergroup Study: Radiation Therapy vs Chemotherapy + Radiation Therapy for Localized SCC or ADC of the Esophagus Schema tumor size histology weight loss R A N D O M I Z E 2 x Cisplatin (75 mg/m 2 ) + 5-fluorouracil (1000 mg/m 2 /d CI x 4d) + radiation therapy (5000 cgy) radiation therapy (6400 cgy) Herskovic A, et al. N Engl J Med. 1992;326: al-sarraf M, et al. J Clin Oncol. 1997;15:
14 Intergroup Study Herskovic A, et al. N Engl J Med. 1992;326: al-sarraf M, et al. J Clin Oncol. 1997;15:
15 Prodige 5 - ACCORD 17 - Schema Inoperable esophageal cancer R A N D O M I Z E 50 Gy/5 weeks + Folfox, 3 cycles 50 Gy/5 weeks + 5FU/cisplatin, 2 cy. Folfox, 3 cycles 5FU/cisplatin, 2 cycles Stratification : adenocarcinoma vs squamous cell vs adenosquamous pretreatment weight loss < 10% vs 10% performance status: 0 vs 1 vs 2 center Conroy et al. Lancet Oncol Mar;15(3):
16 Prodige 5 - ACCORD 17 - Survival FOLFOX: more gr. 1-2 PN, fewer toxic & sudden deaths, less mucositis, less alopecia, decreased renal toxicity, shorter chemotherapy (12 days vs days) in an outpatient setting. Conroy et al. Lancet Oncol Mar;15(3):
17 Chemoradiation Therapy With or Without Surgery: French Phase III Trial A total of 455 patients with localized esophageal cancer were given 2 courses of 5-FU/cisplatin plus radiation therapy. 259/455 patients experienced a partial response, were considered operative candidates, and entered the randomized component of the trial. Bedenne. J Clin Oncol. 2007;25:
18 Chemoradiation Therapy With or Without Surgery: French Phase III Trial 3-month Survival mortality median 2-year Partial Response (259 pts) R A N D O M I Z E 5-FU/CDDP x 3 + 1% Radiation therapy 19.3 months Surgery 9% 17.7 months 40% P= % Bedenne. J Clin Oncol. 2007;25:
19 Chemoradiation Therapy With or Without Surgery: German Phase III Trial - Schema Patients: (N = 177) ut3-4,n0-1, M0 with SCC 3 cycles: 5-FU/LV + Cisplatin + Etoposide R A N D O M I Z E Chemoradiation: Cisplatin + Etoposide + 40 Gy RT Surgery Chemoradiation: Cisplatin + Etoposide + > 60 Gy RT Stahl. J Clin Oncol. 2005;23:
20 Chemoradiation Therapy With or Without Surgery: German Phase III Trial - Results Arm Completed Treatment 3-yr Local Median 3-Year Survival Treatment Mortality Recurrence Survival Induction Chemo All Responder Arm A: C/RT S 62% 12.8% 41% 16 mo. 31% 54% Arm B: C/RT 85% 3.5% 64% 15 mo. 24% 54% (P = 0.03) (P = 0.004) (P = 0.02) Stahl. J Clin Oncol. 2005;23:
21 Chemoradiation Therapy With or Without Surgery: German Phase III Trial - Survival Median survival (N = 172): Arm A (C/RT S) months Arm B (C/RT only)-14.9 months 31.3% (P = 0.02) 24.4% Stahl. J Clin Oncol. 2005;23:
22 Conclusions from these Studies Localized Esophageal Pre-operative cisplatin/5-fu chemotherapy offers a small survival advantage in distal esophageal and GE junction cancer. Neoadjuvant platinum-based chemoradiation (esp. w. carbo/tax) offers a greater survival advantage with better local control but increased surgical morbidity. Surgery may not be needed in patients who have a clinical response to chemoradiation. FOLFOX may be the best choice for these patients.
23 Localized Gastric Cancer What Can Surgery Accomplish?
24 Survival for Resected Localized Gastric Cancer Survival for 10,601 patients with resected gastric cancer using SEER data and AJCC 7 th ed. Washington. Ann Surg Oncol 2010
25 Localized Gastric Cancer What are Proven Strategies to Enhance Outcomes for Surgical Resection?
26 Intergroup Protocol 0116 Adjuvant Therapy for Gastric Cancer Stratify R depth of tumor penetration number involved nodes A N D O M 5-FU/leucovorin x 1 5-FU/leucovorin cgy radiation 5-FU/leucovorin x 2 location of tumor I Z observation extent of surgery E Macdonald JS, et al. N Engl J Med. 2001;345(10):
27 Intergroup Protocol years 41% 50% Chemoradiotherapy Surgery Only Macdonald JS, et al. N Engl J Med. 2001;345: Smalley SR, et al. J Clin Oncol. 2012; 30:
28 MAGIC Trial: Schema Cunningham D, et al. N Engl J Med. 2006;355: Patients: 15% Lower Third 12% GE Junction ECF x 3 q3/ weeks CSC S Within 6 weeks Resection Resection 6-12 weeks ECF x 3 q3/52 Follow-up
29 MAGIC: Survival
30 CALGB 80101: Study Schema R A N D 5-FU/LV X1 5-FU IVCI RT 5-FU/LV X2 O M I ECF 5-FU IVCI ECF Z E X1 RT X2 All pts treated with: RT: 45 Gy (1.8 Gy X 25 fractions) with 5-FU 200 mg/m2/d CI Mayo 5-FU/LV: 5-FU 425 mg/m2 d1-5, LV 20 mg/m2 d1-5 ECF (pre-rt): Epirubicin 50mg/m2 d1, Cisplatin 60mg/m2 d1, & 5-FU 200mg/m2/d1-21 ECF (post-rt): Epirubicin 40mg/m2 d1, Cisplatin 50mg/m2 d1, & 5-FU 200mg/m2/d1-21 Fuchs. ASCO 2011
31 CALGB 80101: Overall Survival by Treatment Arm Overall Survival by Arm Proportion Surviving Years from Study Entry ECF 5-FU P, log rank = 0.80 Fuchs. ASCO 2011
32 ITACA-S: Intensive Adjuvant Chemo vs. 5FU/LV
33 ITACA-S: Intensive Adjuvant Chemo vs. 5FU/LV Despite significantly increased toxicity: Bajetta et al. Ann Oncol 2014; 25:
34 What s going on in SouthEast Asia? CLASSIC TRIAL - Schema Stage II-IIIB Gastric D2 R0 Resection Stratified: Country (S. Korea vs. China vs. Japan) Stage (II vs. IIIa vs. IIIb) N = 520 R N = 515 CAPOX x 8 (6 months): Capecitabine: 1000/m 2 twice daily d1-14; q3 wks Oxaliplatin 130/m 2 d1; q3 weeks Observation Primary endpoint: 3yr Disease-Free Survival Bang et al. Lancet 2012; 379:
35 CLASSIC TRIAL (SE Asia): Survival Disease-Free Survival Overall Survival 5-yr DFS: HR 0.58; p<0.0001) Surgery: 53% (47-58) S+CAPOX: 68% (63-73) 5-yr OS: HR 0.66; p=0.0015) Surgery: 69% (64-73) S+CAPOX: 78% (74-82) Noh et al. Lancet Oncol 2014; 15:
36 ARTIST TRIAL (S. Korea): Schema Stage IB-IV(M0) Gastric D2 R0 Resection Stratified: Not stated N = 228 R N = 230 XP x 6 cycles (18 weeks): Capecitabine 2000mg/2; d1-14 (q3weeks) Cisplatin 60mg/m2; d1 (q3weeks) XP/XRT/XP (17+ weeks): XP x 2 cycles XRT 45Gy / Cape 1650mg/m2 x 5 weeks XP x 2 cycles Primary endpoint: Disease-Free Survival Lee et al. J Clin Oncol 2012: 30(3);
37 ARTIST Trial (S. Korea) : Efficacy Disease-Free Survival Overall Survival DFS: 0.74; p= yr DFS: 74% vs. 78% OS: 1.13; p= yr OS:73% vs. 75% How applicable is this in the West? Lee et al. J Clin Oncol 2012: 30(3);
38 Conclusions from these Results Localized Gastric: Post-operative 5-FU-based chemoradiation therapy remains the standard of care for muscle-invasive or LN positive disease. The MAGIC trial demonstrates that pre- and post-operative ECF improves survival. It may be particularly beneficial for downstaging extensive local disease. More aggressive chemotherapy is not better. Unclear how applicable data from SE Asia is for Western patients.
39 Metastatic Esophagogastric Cancer What are the Active Agents and Combinations for this Disease?
40 Evolution of Therapy in Advanced Esophagogastric Cancer Randomized Phase III Randomized Phase II Multi-center Phase II 5-FU < FAM FAM < FAMTX CF = ELF = FAMTX > EAP FOLFOX DC < DCF IP < FOLFIRI PELF = FAMTX < ECF FOL = CF FOX DCF > CF CF = FOLFIRI ECF > MCF FOL =ECF FOX mdcf FOLFIRI = EOX ECF = ECX = EOF = EOX
41 CALGB / ECOG E1206: Schema ARM A: (ECF + cetuximab); 1 cycle = 21 days Cetuximab mg/m2 IV, weekly Epirubicin 50 mg/m2 IV, day 1 Cisplatin 60mg/m2 IV, day 1 Fluorouracil 200mg/m2/day, days 1-21 Stratification: ECOG 0-1 vs 2 ADC vs. SCC ARM B: (IC + cetuximab); 1 cycle = 21 days Cetuximab mg/m2 IV, weekly Cisplatin 30 mg/m2 IV, days 1 and 8 Irinotecan 65 mg/m2 IV, days 1 and 8 ARM C: (FOLFOX + cetuximab); 1 cycle = 14 days Cetuximab mg/m2 IV, weekly Oxaliplatin 85 mg/m2 IV, day 1 Leucovorin 400 mg/m2, day 1 Fluorouracil 400 mg/m2 IV bolus, day 1 Fluorouracil 2400 mg/m2 IV over 46hrs (days 1-2) Enzinger. J Clin Oncol 2016
42 CALGB / E1206: Survival FOLFOX-C has similar efficacy to ECF-C in Esophageal and GEJ Cancer Progression-Free Survival Overall Survival Probability Progression-free Survival Events Median 95% CI n/n (%) months ECF-C 65/67 (97.0%) IC-C 72/73 (98.6%) FOLFOX-C 70/73 (95.9%) Log-rank test p= Months from Study Entry Probability Overall Survival Events n/n (%) Median 95% CI months ECF-C 63/67 (94.0%) IC-C 68/73 (93.2%) FOLFOX-C 65/73 (89.0%) Log-rank test p= Months from Study Entry Number of Patients at Risk ECF-C IC-C FOLFOX-C Number of Patients at Risk ECF-C IC-C FOLFOX-C Treatment modifications: FOLFOX-C (73%) vs IC-C (85%) vs ECF-C (91%) (χ 2, p=0.013). Discontinued treatment for adverse event or treatment-related death: FOLFOX-C (11%) vs. ECF-C (19%) vs IC-C (26%) (χ 2, p=0.17). Enzinger. J Clin Oncol 2016
43 Phase III: DCF vs CF for Esophagogastric Cancer Time to Progression Overall Survival Grade 3-4 Toxicity DCF CF Neutropenia 82% 57% Febrile Neutropenia 29% 12% Stomatitis 21% 27% Diarrhea 19% 8% Vomiting 14% 17% Van Cutsem et al. J Clin Oncol 2006
44 Randomized PII: Modified DCF vs. DCF for Met Gastric Grade 3-4 Toxicity mdcf DCF Neutropenia w GCSF 56% 45% Febrile Neutropenia 9% 16% Stomatitis 0 13% Diarrhea 6% 3% Vomiting 2% 19% Shah et al. JCO 2015;33:
45 Phase 3: FOLFIRI vs ECX for Met Gastric/GEJ Guimbaud. J Clin Oncol 2014
46 REAL-2: Schema Previously untreated patients with locally advanced or metastatic oesophagogastric cancer Stratified for: R A N D O M I S A T I O N - Center (63 centers, mainly UK, 2 Aus) - Locally advanced vs metastatic - PS 0/1 vs 2 2 x 2 design Epirubicin Cisplatin Fluorouracil Epirubicin Cisplatin Xeloda (capecitabine) Epirubicin Oxaliplatin Fluorouracil Epirubicin Oxaliplatin Xeloda (capecitabine) Cunningham D, et al. N Engl J Med. 2008;358:36-46.
47 REAL-2: Survival (ITT) 100 Arm OS (m) 1-year survival (95% CI) P-value HR (95% CI) Probability of survival (%) ECF EOF ECX EOX ( ) 40.4 ( ) 40.8 ( ) 46.8 ( ) EOX ( ) 0.92 ( ) 0.80 ( ) 20 ECF Time since randomisation (years) Cunningham D, et al. N Engl J Med. 2008;358: ECF EOF ECX EOX
48 ToGA - Schema Phase III, randomized, open-label, international, multicenter study 3807 patients screened HER2-positive (22.1%) Stratification factors Advanced vs metastatic GC vs GEJ Measurable vs non-measurable ECOG PS 0-1 vs 2 Capecitabine vs 5-FU HER2-positive advanced GC (n = 584) R 5-FU or capecitabine + cisplatin (n = 290) 5-FU or capecitabine a + cisplatin + trastuzumab (n = 294) a Chosen at investigator s discretion GEJ, gastroesophageal junction Bang, Y-J et al. Lancet 2010; 376:687
49 ToGA: Overall Survival 2.7 mo. (HER2 3+ or 2+/FISH+)
50 Metastatic Esophagogastric Cancer Is 2 nd line therapy of benefit?
51 Cougar-02: Randomized Trial of Docetaxel vs. BSC in Relapsed Esophagogastric Adenocarcinoma 168 patients : R A N D O M I Z E Docetaxel 75 mg/m 2 q 3 weeks Best supportive care Primary Endpoint: Overall Survival Ford et al. Lancet Oncol Jan;15(1):78-86.
52 Cougar 02: 2 nd line Docetaxel vs. BSC: Overall Survival 3.6 mo 5.2mo HR: 0.67, 95% CI ; p=0.01 Ford et al. Lancet Oncol Jan;15(1):78-86.
53 REGARD Study Design S C R E E N R A N D O M I Z E N = 355 2:1 Ramucirumab 8 mg/kg q2wk + BSC (n = 238) Placebo q2wk + BSC (n = 117) Treatment until disease progression or intolerable toxicity Tumor assessment, survival, and safety followup Multicenter, randomized, double-blind, placebo-controlled, phase 3 trial Gastric or GEJ adenocarcinoma Stratification factors: region, weight loss ( 10% vs. <10% over 3 months), location of primary tumor (gastric vs. GEJ) Global: 6 continents, 30 countries, 120 study centers Abbreviations: BSC=best supportive care; GEJ= gastroesophageal junction Fuchs et al. Lancet Jan 4;383(9911):31-9.
54 REGARD: Overall Survival 1.0 HR (95% CI) = (0.603, 0.998) Log rank P-value (stratified) = Overall Survival Ramucirumab Placebo Patients / Events 238 / / 99 Median (mos) (95% CI) 5.2 (4.4, 5.7) 3.8 (2.8, 4.7) 6-month OS 42% 32% 12-month OS 18% 11% Δ mos = 1.4 months Ramucirumab Placebo Censored Censored Months No. at Risk Ram Plcb Fuchs et al. Lancet Jan 4;383(9911):31-9.
55 Wilke et al. Lancet 2014; 15: RAINBOW: Study Design S C R E E N 1:1 R A N D O M I Z E Ramucirumab 8 mg/kg day 1&15 + Paclitaxel 80 mg/m 2 day 1,8 &15 of a 28-day cycle N = 330 Placebo day 1&15 + Paclitaxel 80 mg/m 2 day 1,8 &15 N = 335 Treat until disease progression or intolerable toxicity Survival and safety followup Important inclusion criteria: - Metastatic or loc. adv. unresectable gastric or GEJ* adenocarcinoma - Progression after 1 st line platinum/fluoropyrimidine based chemotherapy Stratification factors: - Geographic region, - Measurable vs non-measurable disease, - Time to progression on 1 st line therapy (< 6 mos vs. 6 mos) * GEJ= gastroesophageal junction; gastric and GEJ will be summarized under the term GC
56 RAINBOW: Overall Survival HR (95% CI) = (0.678, 0.962) Stratified log rank p-value = RAM + PTX PBO + PTX Patients / Events 330 / / 260 Median(mos) (95% CI) 9.63 (8.48, 10.81) 7.36 (6.31, 8.38) 6-month OS 72% 57% 12-month OS 40% 30% Δ mos = 2.3 months Censored No. at risk RAM + PTX PBO + PTX Wilke et al. Lancet 2014; 15:
57 Presented by:
58 Keynote -012: Pembrolizumab for GEJ and Gastric Muro et al. Lancet Oncol 2016; 17:717-26
59 Keynote -012: Pembrolizumab for GEJ and Gastric Progression-Free Survival Overall Survival Muro et al. Lancet Oncol 2016; 17:717-26
60 ONO-4538: Phase 3 Study of Nivolumab vs Placebo in Patients With Refractory GC Key eligibility criteria: Age 20 years Unresectable advanced or recurrent GC or GJC Histologically confirmed adenocarcinoma Prior treatment with 2 regimens and refractory to/intolerant of standard therapy ECOG PS of 0 or 1 Study Design and Endpoints R 2:1 Nivolumab 3 mg/kg IV Q2W Placebo Primary endpoint OS Secondary endpoints Efficacy Safety Exploratory endpoint Biomarkers Stratification based on: Country (Japan vs Korea vs Taiwan) ECOG PS (0 vs 1) Number of organs with metastases (<2 vs 2) Patients were permitted to continue treatment beyond initial RECIST v1.1-defined disease progression as assessed by the investigator if receiving clinical benefit and tolerating study drug. Adapted from presentation by Yoon-Koo Kang, Gastrointestinal Cancers Symposium, Kang Y-K et al. J Clin Oncol. 2017;35(suppl 4):abstract 2.
61 ONO-4538: Overall Survival Patients n Events n Median OS Mos. 95% CI) 12-Month OS % (95% CI) Probability of survival (%) Patients at risk: Nivolumab 330 Placebo Nivolumab ( ) Placebo ( ) Placebo Time (months) HR = 0.63 (95% CI, ) P< Nivolumab ( ) 10.9 ( ) Adapted from presentation by Yoon-Koo Kang, Gastrointestinal Cancers Symposium, Kang Y-K et al. J Clin Oncol. 2017;35(suppl 4):abstract 2.
62 ONO-4538: Progression-Free Survival Probability of PFS (%) Patients at risk: Nivolumab 330 Placebo 163 Placebo Patients n Events n 10 Time (months) Median PFS Mos. (95% CI) Nivolumab ( ) Placebo ( ) HR = 0.60 (95% CI, ) P< Nivolumab Month PFS % (95% CI) ( ) 1.5 ( ) Adapted from presentation by Yoon-Koo Kang, Gastrointestinal Cancers Symposium, Kang Y-K et al. J Clin Oncol. 2017;35(suppl 4):abstract 2.
63 Conclusions from these Results Metastatic Esophagogastric: The most active single agents are the fluoropyrimidines, platinum analogues, taxanes, and irinotecan. 1 st Line: Fluoropyrimidine & platinum combos are standard. Trastuzumab should be added for HER2/neu 3+ or FISH+ tumors. Pts should receive at least 2 lines of therapy for their dz. 2 nd Line: Paclitaxel + Ramucirumab is probably the best choice for most patients. Checkpoint inhibitors are effective in esophagogastric cancer.
64 Pancreatic Cancer: Staging and Prognosis Stage classification % at diagnosis 5-year survival Localized 8 20% Locally advanced/ unresectable 31 8% Metastatic 61 2%
65 GITSG: Addressing the Role of Adjuvant 5-FU Based Chemoradiation in Pancreatic Cancer Median survival: 20 vs 11 months (P = 0.03) 2 yr survival 43 vs. 18% (4000 cgy XRT in splitcourse with concurrent 5-FU, followed by weekly 5-FU x 2 years) Note: based on 43 patients only, accrued over 8 years. Study terminated prematurely before reaching original accrual goal. Kalser MH, et al. Arch Surg. 1985;120:
66 ESPAC: European Study Group for Pancreatic Cancer N = x 2 factorial design pooled analysis Median survival, chemo vs no chemo: 20.1 vs 15.5 months Median survival, chemoxrt vs no chemoxrt: 15.9 vs 17.9 months Authors conclusions: chemotherapy produces survival benefit s/p pancreatic ca resection; whereas chemoradiation has deleterious effect Observation (69) Chemotherapy (75) ChemoXRT (73) ChemoXRT chemotherapy (72) - Chemotherapy regimen: 5FU/LV monthly x 6 - Chemoradiation regimen: 4000 cgy XRT (split course) with concurrent 5-FU Neoptolemos JP, et al. N Engl J Med. 2004;350(12):
67 CONKO-001 TRIAL 71% node (+) 81% R0 resection Resected pancreatic cancer (N = 368) Stratified by age, tumor status, nodal status, resection margin Gemcitabine x 6 months (n = 186) Observation (n = 182) Oettle.JAMA. 2007;297: Oettle.JAMA Oct 9;310(14): % node (+) 85% R0 resection 5yr DFS: 16.6% vs. 7.0% 5yr OS: 20.7% vs. 12.2%
68 ESPAC-4: Schema R0/R1 Resected Panc Adenoca WHO <2; <12 wks N= 730 R A N D O M IZ Stratify: R0 vs R1, Country (UK vs rest) Primary Endpoint: Overall survival E Gemcitabine 1,000 mg/m 2 d 1,8,15 q4 wks x6 (N= 366) Gemcitabine + Capecitabine 1,660mg/m 2 d1-21 q4 wks x6 (N= 364) Stratified log-rank 5% 2-sided alpha for 10% diff 2 year survival (47.5% 57.5%, 90% power with 480 deaths, planned N= 722) Neoptolemos. Annu Mtg Proc Am Soc Clin Oncol 2016
69 ESPAC-4: Overall Survival Neoptolemos. Annu Mtg Proc Am Soc Clin Oncol 2016
70 Should Neoadjuvant Therapy be Considered for Operable Disease? THEORETICAL ADVANTAGES OVER POSTOPERATIVE TREATMENT Improved rate of negative surgical margins No prolonged postoperative recovery before administering treatment In older postop studies, ~20-25% of patients intended for adjuvant therapy do not end up receiving it Patients with distant metastases on restaging are spared the morbidity of surgery Allows testing of novel agents for on-target tumor effects MD Anderson experience: approx 66% of patients make it to surgery with a 2-4 months course of preop chemoxrt; of these, median OS = months (Evans DB. J Clin Oncol. 2008;26: Varadhachary GR. J Clin Oncol. 2008;26: ) MAJOR CONCERN: delay of only potentially curative option (surgery)
71 Locally Advanced Pancreas Cancer Distant metastasis (including non-regional lymph node metastasis) Head/uncinate process: Solid tumor contact with SMA or celiac axis >180 o Solid tumor contact with the first jejunal SMA branch Thrombosis of SMV or portal vein Contact with most proximal jejunal branch of SMV Body and tail: Solid tumor contact of >180 o with the SMA or celiac axis Solid tumor contact with the celiac axis and aortic involvement Thrombosis of SMV or portal vein NCCN Guidelines Version
72 LAP 07 - SCHEMA Random 1 EVALUATION : non progressive EVALUATION : non progressive Random 2 Cape RT Cape EVALUATION EVALUATION EVALUATION Until Progression RT 1 month = Gemcitabine 1000 mg/m 2 /wk x 3 Erlotinib with gem : 100 mg/d Cape RT Capecitabine 1600 mg/m 2 /d plus radiation therapy 54 Gy (5 x 1.8 Gy/d) 150 mg/d as single agent (maintenance) Secondary surgery allowed at any time Hammel. JAMA 2016 May 3;315(17):
73 LAP 07 Survival Overall Survival Progression-Free Survival Hammel. JAMA 2016 May 3;315(17):
74 Should FOLFIRINOX Therapy be Considered for Inoperable Disease? MGH experience: 22 patients with LAPC treated with FOLFIRINOX between July 2010 and February ORR was 27.3%, and median PFS was 11.7 months. R0 resection: 5 of 22 patients (23%) Recurrence: 3 of 5patients with distant recurrence within 5 months. Hospitalization: 32% on FOLFIRINOX. Faris et al. Oncologist. 2013;18(5):543-8.
75 Conclusions from these Results: Localized Pancreatic: Adjuvant gemcitabine therapy is most important in the postoperative treatment of resected pancreas cancer. The addition of capecitabine appears to improve survival. C/RT presently plays a lesser role and is given at most centers now at the end of an adjuvant treatment course. Neoadjuvant C/RT remains experimental. Unresectable dz is rarely converted with this approach. Pts with LAPC can be treated with chemo alone or chemo C/RT. FOLFIRINOX may improve resectability but long-term survival is?
76 Treatment of Metastatic Disease: Can We move beyond Gemcitabine? Gemcitabine approved in 1997 for first-line therapy of advanced PADC Median survival (vs bolus 5-FU): 5.65 vs 4.41 mos. (P = ) 1-yr survival: 18% vs 2% Clinical benefit: 23.8% vs 4.8% RR: 5.4% vs 0% Burris HA. J Clin Oncol. 1997;15:
77 What About Combination Therapy?: Gemcitabine/Platinum Doublets for Advanced Pancreatic Cancer (Phase III Trials) Gruppo Oncologia dell Italia Meridionale Study (n = 107) German Multicentre Study (n = 190) GERCOR/GISCAD Intergroup Study (n=313) ECOG 6201 (n=833) * Third arm = FDR gem Treatment Progression-free survival Gemcitabine 8 wks 5 mos Median survival Gemcitabine/cisplatin 20 wks (p=0.048) 7.5 mos (P = 0.48) Combined analysis: gemcitabine/platinum results in significant improvement in overall survival (HR 0.85, P = 0.01) Gemcitabine 3.1 mos 6.0 mos Gemcitabine/cisplatin 5.3 mos (p=0.053) 7.5 mos (P = 0.15) Gemcitabine 3.7 mos 7.1 mos Gemcitabine/oxaliplatin 5.8 mos (p=0.04) 9.0 mos (P = 0.13) Gemcitabine N/A 4.9 mos Heinemann et al, BMC Cancer 2008 Gemcitabine/oxaliplatin N/A 5.9 mos Viret et al (n=83) Gemcitabine 2.5 mos 6.7 mos Gemcitabine/cisplatin 2.2 mos (p=ns) 8.0 mos (P = 0.73)
78 Other Gemcitabine-Based Doublets: Phase III Trials of GEM-CAP VS Gemcitabine GEM-CAP Gemcitabine Statistically significant? Cunningham D, et al. J Clin Oncol. 2009; 27: N Combined analysis: gemcitabine/capecitabine results in significant improvement in overall survival (HR, 0.86; P = 0.02) Cunningham, J Clin Oncol 2009 Med survival 7.1 months 6.2 months P = 0.08 Herrmann R, et al. J Clin Oncol. 2007;25: (SAKK study) N Med survival 8.4 months 7.2 months P = (SAKK study, post hoc analysis on pts with KPS ) N Med survival P = 0.014
79 Phase III Study of Gemcitabine + Erlotinib in Advanced Pancreatic Cancer (NCIC PA.3) Moore MJ, et al. J Clin Oncol. 2007;25:
80 NCIC PA.3: SURVIVAL RESULTS Moore MJ, et al. J Clin Oncol. 2007;25: PFS: 3.75 vs 3.55 months (P = 0.004) RR: 8.6 vs 8.0% (P = NS)
81 Prodige 4 -ACCORD 11/0402: Gemcitabine vs. FOLFIRINOX R Gemcitabine 1000 mg/m2 qwk x 7/8, then qwk x 3/4 30 min 2 h Bolus 5-FU 400 mg/m 2 Oxaliplatin Leucovorin Continuous 5-FU 85 mg/m mg/m mg/m 2 Irinotecan 2 h 180 mg/m 2 46 h q2wks 1 h 30 Conroy. N Engl J Med. 2011;364(19):
82 PRODIGE 4: Objective Response Rate Folfirinox N=171 Gemcitabine N=171 p Complete response 0.6% 0% Partial response 31% 9.4% CR/PR 95% CI [ ] [ ] Stable disease 38.6% 41.5% Disease control CR+PR+SD 70.2% 50.9% Progression 15.2% 34.5% Not assessed 14.6% 14.6% Median duration of response 5.9 mo. 4 mo. ns Conroy. N Engl J Med. 2011;364(19):
83 PRODIGE 4: Overall Survival 3.3 vs. 6.4 mos 6.8 vs mos Conroy. N Engl J Med. 2011;364(19):
84 MPACT: Study Design Planned N = 842 Stage IV No prior treatment for metastatic disease KPS 70 Measurable disease Total bilirubin ULN Primary Endpoint: OS Secondary Endpoints: PFS and ORR by Independent Review (RECIST) Safety and Tolerability by NCI CTCAE v3.0 nab-paclitaxel 125 mg/m 2 IV qw 3/4 weeks + Gemcitabine 1000 mg/m 2 IV qw 3/4 weeks 1:1, stratified by KPS, region, liver metastasis Gemcitabine 1000 mg/m 2 IV qw for 7/8 weeks then qw 3/4 weeks With 608 events, 90% power to detect OS HR = (2 sided α = 0.049) 1 interim analysis for futility Treat until progression CT scans every 8 weeks Von Hoff et al., N Engl J Med Oct 31;369(18):
85 MPACT: Response Rates Variable nab-p + Gem (n = 431) Gem (n = 430) P-value Overall Response Rate Independent Review, % (95% CI) Investigator Assessment, % (95% CI) 23 ( ) 29 ( ) 7 ( ) 8 ( ) 1.1x x10-16 Disease Control Rate by Independent Review, a % (95% CI) 48 ( ) 33 ( ) 7.2x10-6 a Includes CR + PR + SD 16 weeks PRODIGE 4 Folfirinox N=171 Gemcitabine N=171 p Complete response 0.6% 0% Partial response 31% 9.4% CR/PR 95% CI [ ] [ ] Disease control CR+PR+SD 70.2% 50.9% Von Hoff et al., N Engl J Med Oct 31;369(18):
86 MPACT: Overall Survival Proportion of Survival Pts at Risk nab-p + Gem: Gem: nab-p + Gem Gem Events/N (%) Months OS, months Median (95% CI) th Percentile 333/431 (77) ( ) /430 (83) ( ) 11.4 FOLFIRINOX vs. Gem 0.57 HR = % CI ( ) P = Von Hoff et al., N Engl J Med Oct 31;369(18):
87 Safety: FOLFIRINOX vs. Gemcitabine vs. G+Nab-Paclitaxel Prodige 4 G3-4 Toxicity FOFIRINOX Gemcitabine ANC 45.7% 18.7% Febrile ANC 5.4% 0.6% Received GCSF 42.5% 5.3% Anemia 7.8% 5.4% Plts 9.1% 2.4% Fatigue 23.2% 14.2% Peripheral Neuro 9% 0.6% Diarrhea 12.7% 1.2% Death 0.6% 0.6% MPACT Gemcitabine G+Nab-Paclitaxel 27% 38% 1% 3% 15% 26% 12% 13% 9% 13% 7% 17% <1% 17%* 1% 6% 4% 4% *Median time to improvement to Grade <1 = 29 days
88 Wang-Gillam et al. Lancet 2016 Feb 6;387(10018):545-57
89 Response Rate: MM-398+5FU/LV: 16% 5FU/LV: 1% Wang-Gillam et al. Lancet 2016 Feb 6;387(10018):545-57
90 Wang-Gillam et al. Lancet 2016 Feb 6;387(10018):545-57
91 Conclusions from these Results Metastatic Pancreatic: Gemcitabine monotherapy remains an acceptable treatment option for older or asymptomatic pts. Addition of platinum or capecitabine boosts response and PFS but compromises 2 nd line CAPOX or FOLFOX*. Addition of Nab-paclitaxel improves OS but is more toxic. Unclear how would compare to FOLFIRINOX. FOLFIRINOX has best response and survival but is most toxic. It should be considered for stronger, symptomatic pts or potentially resectable disease. MM398+5FU is an option after Gem+Nab-paclitaxel. Unclear if any benefit after FOLFIRINOX. *Pelzer et al. Eur J Cancer Jul;47(11):
Systemic Treatments for Esophagogastric and Pancreas Cancer in the Adjuvant and Metastatic Settings
Systemic Treatments for Esophagogastric and Pancreas Cancer in the Adjuvant and Metastatic Settings Peter C. Enzinger, MD Dana-Farber Cancer Institute & Harvard Medical School 2018 Master Class Course
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationOverview. What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013
What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013 Overview Staging and Workup Resectable Disease Surgery Adjuvant therapy Locally
More informationUpdated Apr 2017 by Dr. Ko (Medical Oncologist, Abbotsford Cancer Centre)
Metastatic Esophagogastric Cancer Summary Updated Apr 2017 by Dr. Ko (Medical Oncologist, Abbotsford Cancer Centre) Reviewed by Dr. Yoo-Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer Centre, University
More informationChemotherapy for Advanced Gastric Cancer
Chemotherapy for Advanced Gastric Cancer Andrés Cervantes Professor of Medicine DISCLOSURE OF INTEREST Employment: None Consultant or Advisory Role: Merck Serono, Roche, Beigene, Bayer, Servier, Lilly,
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationGastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.
Gastroesophageal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. Haddock M.D. Mayo Clinic Rochester, MN Locally Advanced GE Junction ACA CT S CT or CT S CT/RT Proposition Chemoradiation
More informationWhat Is The Optimal Adjuvant Therapy in Pancreatic Adenoca: Intensified Chemotherapy March 28 th, 2015
What Is The Optimal Adjuvant Therapy in Pancreatic Adenoca: Intensified Chemotherapy March 28 th, 2015 Eileen M. O Reilly, M.D. Associate Director David M. Rubenstein Center Pancreatic Cancer Research
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationCHEMOTHERAPY FOR METASTATIC GASTRIC CANCER
CHEMOTHERAPY FOR METASTATIC GASTRIC CANCER Dr Elizabeth Smyth Royal Marsden, UK ESMO Gastric Cancer Preceptorship Valencia 2017 IMPORTANT CONSIDERATIONS WHEN TREATING ADVANCED GASTRIC CANCER Short OS Pain
More informationCurrent standards of care in gastric cancer
Current standards of care in gastric cancer Prof Eric Van Cutsem, MD, PhD Digestive Oncology Leuven, Belgium Eric.VanCutsem@uzleuven.be Outline Resectable gastric cancer: the role of neoadjuvant and adjuvant
More informationPancreatic Ca Update
Pancreatic Ca Update Caio Max S. Rocha Lima, M.D. M. Robert Cooper Professor in Medical Oncology Co-leader GI Oncology and Co-leader Phase I Program Wake Forest School of Medicine E-mail:crochali@wakehealth.edu
More informationGetting to the Bottom of Treatment: An Update in the Management of Esophagogastric Cancers
Getting to the Bottom of Treatment: An Update in the Management of Esophagogastric Cancers Disclosures None Cindy L. O Bryant, PharmD, BCOP, FCCP, FHOPA Professor, University of Colorado Skaggs School
More informationReference No: Author(s) 12/05/16. Approval date: committee. June Operational Date: Review:
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Pancreatic Adenocarcinoma Dr Colin Purcell, Consultant Medical Oncologist & on behalf of the GI Oncologists Group, Cancer
More informationPancreatic Adenocarcinoma
Pancreatic Adenocarcinoma AProf Lara Lipton 28 April 2018 Percentage alive 5 years after diagnosis for men and women Epidemiology 6% of cancer related deaths worldwide 4 th highest cause of cancer death
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationThe role of chemoradiotherapy in GE junction and gastric cancer. Karin Haustermans
The role of chemoradiotherapy in GE junction and gastric cancer Karin Haustermans Overview Postoperative chemoradiotherapy Preoperative chemoradiotherapy Palliative radiation Technical aspects Overview
More informationNeo- and adjuvant treatment for gastric cancer: The role of chemotherapy
Anna Dorothea Wagner, PD & MER Department of Oncology University of Lausanne Neo- and adjuvant treatment for gastric cancer: The role of chemotherapy Structure 1. Background and overview 2. Adjuvant chemotherapy:
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationSystemic treatment in early and advanced gastric cancer
Systemic treatment in early and advanced gastric cancer Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer n Surgical resection n Pathology assessment and estimation
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationPancreas Cancer Update Systemic Treatments
Pancreas Cancer Update Systemic Treatments Carlos R Becerra. Baylor University Medical Center Stage Distribution for Pancreas Cancer in the US (24-21) 1 9 8 7 Axis Title 6 5 4 53 3 28 2 1 9 11 Localized
More informationNeo- and adjuvant treatment for gastric cancer: The role of chemotherapy
Neo- and adjuvant treatment for gastric cancer: The role of chemotherapy Priv. Doz. Dr. Dr. med. T.O. Götze Institute of Clinical Cancer Research Director: Prof. Dr. S.-E. Al- Batran University Cancer
More informationGastric: 16% 18% 27% Esophageal: 5% 10% 19%
2.5% of all cancers Median age 68 years Decline in gastric cancer incidence Increase in esophageal, GEJ, cardia adenocarcinoma OS improvement, 1975-77, 1984-86, 1999-2006 Gastric: 16% 18% 27% Esophageal:
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More informationUpper Gastrointestinal. Friday, March 2, :00 p.m. 2:45 p.m.
Upper Gastrointestinal Friday, March 2, 2018 2:00 p.m. 2:45 p.m. Social Q&A Use your phone, tablet, or laptop to Submit questions to speakers and moderators Answer interactive questions / audience response
More informationJonathan Dickinson, LCL Xeloda
Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy
More informationESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT
ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT DOCETAXEL, OXALIPLATIN AND FLUOROURACIL/LEUCOVORIN (FLOT) FOR RESECTABLE
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationPerioperative versus adjuvant management of gastric cancer, update 2013
Perioperative versus adjuvant management of gastric cancer, update 2013 Cornelis J.H. van de Velde, MD, PhD,FRCPS and FACS,Hon. Professor of Surgery President ECCO - the European Cancer Organization Past-President
More informationWhich Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy
Which Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy Joseph Chao, M.D. Assistant Clinical Professor Department of Medical Oncology & Therapeutics
More informationPerioperative chemotherapy: individualized therapy or same treatment for all? Prof. Dr. med. Salah-Eddin Al-Batran
Perioperative chemotherapy: individualized therapy or same treatment for all? Prof. Dr. med. Salah-Eddin Al-Batran Institute of Clinical Cancer Research Krankenhaus Nordwest UCT - University Cancer Center
More informationConcept to Practice: New Advances in the Treatment of GI Cancers
Concept to Practice: New Advances in the Treatment of GI Cancers 2016 Community Oncology Alliance Conference Orlando, FL Thomas George, MD, FACP Director, GI Oncology Program Director, Experimental Therapeutics
More informationAdjuvant therapy in pancreatic cancer Monotherapy for whom? JL VAN LAETHEM, MD,PhD
Adjuvant therapy in pancreatic cancer Monotherapy for whom? JL VAN LAETHEM, MD,PhD Efficacy Parameters in adjuvant monochemotherapy Randomized studies in resectable PDAC Regimen DFS HR (p) OS HR (p) 5-yr-OS
More informationCurrent Standard of Care of Gastric Cancer:
Current Standard of Care of Gastric Cancer: Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation of risk Treatment
More informationThe 2010 Gastrointestinal Cancers Symposium Oral Abstract Session: Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract
The 2010 Gastrointestinal Cancers Symposium : Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract Abstract #131: Phase I study of MK 0646 (dalotuzumab), a humanized monoclonal antibody against
More informationAdjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009
HIGHLIGHT ARTICLE - Slide Show Adjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009 Muhammad Wasif Saif
More informationTough to treat tumors in elderly. how far can we go? Jean-Luc Raoul Institut Paoli-Calmettes Marseille France
Tough to treat tumors in elderly Pancreatic cancer: how far can we go? Jean-Luc Raoul Institut Paoli-Calmettes Marseille France Top 5 causes of cancer death / age Cancer Statistics in the USA 2008, CA
More informationUpper Gastrointestinal Cancers in the Elderly. Choo Su Pin Senior Consultant Medical Oncology National Cancer Centre Singapore
Upper Gastrointestinal Cancers in the Elderly Choo Su Pin Senior Consultant Medical Oncology National Cancer Centre Singapore Gastric Cancer --High Global Burden Global Cancer Deaths % of all cancer (2008)
More informationNewly Diagnosed Cases Cancer Related Death NCI 2006 Data
Multi-Disciplinary Management of Esophageal Cancer: Surgical and Medical Steps Forward Alarming Thoracic Twin Towers 200000 150000 UCSF UCD Thoracic Oncology Conference November 21, 2009 100000 50000 0
More informationHeterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
More informationAdvances in Chemotherapy of Colorectal Cancer
Advances in Chemotherapy of Colorectal Cancer Richard M. Goldberg Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Disease Settings Adjuvant Therapy MOSAIC, FOLFOX Andre
More informationAre we making progress? Marked reduction in operative morbidity and mortality
Are we making progress? Surgical Progress Marked reduction in operative morbidity and mortality Introduction of Minimal-Access approaches for complex esophageal cancer resections Significantly better functional
More informationSBRT in Pancreas Cancer Role of The Radiosurgery Society
SBRT in Pancreas Cancer Role of The Radiosurgery Society Anand Mahadevan MD FRCS FRCR Chairman Division of Radiation Oncology Geisinger Health System, Danville, PA, USA. Past President and Chairman: The
More informationResectable locally advanced oesophagogastric cancer
Resectable locally advanced oesophagogastric cancer Clinical Case Discussion Florian Lordick University Cancer Center Leipzig University Clinic Leipzig Leipzig, Germany esmo.org DISCLOSURES Honoraria for
More informationCurrent Standard of Care of Gastro- Esophageal Cancer
Current Standard of Care of Gastro- Esophageal Cancer Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation of risk
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationManagement of Squamous Cell Cancer of the Esophagus: Surgery Should Follow Chemo + RT
Management of Squamous Cell Cancer of the Esophagus: Surgery Should Follow Chemo + RT David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan Kettering Cancer Center Disclosure Consulting
More informationUpdates and best practices in the management of gastric cancer
Updates and best practices in the management of gastric cancer Olatunji B. Alese, MD Gastrointestinal Oncology, Winship Cancer Institute of Emory University July 28, 2017 1 Incidence 3rd leading cause
More informationUpdated Apr 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre)
Local Esophageal Cancer Summary Updated Apr 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre) Reviewed by Dr. Yoo-Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer Centre, University
More informationConflicts of Interest GI Malignancies: An Update on Current Treatment Options
Conflicts of Interest GI Malignancies: An Update on Current Treatment Options Nothing to disclose Trevor McKibbin, PharmD, MS, BCOP Clinical Specialist, Hematology/Oncology Winship Cancer Institute of
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationCALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
More informationPancreatic Cancer and Radiation Therapy
Pancreatic Cancer and Radiation Therapy Why? Is there a role for local therapy with radiation in a disease with such a high rate of distant metastases? When? Resectable Disease Is there a role for post-op
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationAdjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationLA CHEMIOTERAPIA DI I LINEA
DECIDERE LA CHEMIOTERAPIA ADIUVANTE E DELLA MALATTIA METASTATICA LA CHEMIOTERAPIA DI I LINEA Michele Reni Department of Medical Oncology IRCCS Ospedale San Raffaele Milan, Italy 1930 1940 1950 1960 1970
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationPCPA Advanced Trainee Program Upper GI Cancers. Dr N Singhal Medical Oncologist Royal Adelaide Hospital
Upper GI Cancers Dr N Singhal Medical Oncologist Royal Adelaide Hospital Localised disease PCPA Advanced Trainee Program 2018 Submucosal PCPA Advanced Trainee Program 2018 Work up EUS- 90% sensitivity
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationPrinted by Hadi Ranjkeshzadeh on 11/12/2010 4:40:23 PM. For personal use only. Not approved for distribution. Copyright 2010 National Comprehensive
Discussion Categories of Evidence and Consensus Category 1: The recommendation is based on high-level evidence (e.g. randomized controlled trials) and there is uniform consensus. Category 2A: The recommendation
More informationintent treatment be in the elderly?
Gastric cancer: How strong can curative intent treatment be in the elderly? Caio Max S. Rocha Lima, M.D. Professor of Medicine University of Miami & Sylvester Cancer Center Gastric cancer: epidemiology
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationCáncer de Páncreas: Optimización del tratamiento sistémico
Cáncer de Páncreas: Optimización del tratamiento sistémico Alfredo Carrato Hospital Universitario Ramón y Cajal, Madrid 16 de Mayo de 2015 Pancreatic cancer screening There is a latency period of about
More informationReference No: Author(s) Approval date: 12/05/16. Committee. June Operational Date: Review:
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Biliary Tract Cancer (BTC) Dr Colin Purcell, Consultant Medical Oncologist on behalf of the GI Oncologists Group, Cancer
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationCa Cardias e Stomaco: le diversita e le terapie
XXII Riunione Nazionale I.T.M.O. Ca Cardias e Stomaco: le diversita e le terapie Maria Di Bartolomeo s.s. Oncologia Medica Gastroenterologica Fondazione IRCCS Istituto Nazionale Tumori Milano OUTLINE History
More informationPancreatic Cancer. BIOLOGY: Not well defined (genetic and enviromental factors) CLINICAL PRESENTATION: Abd pain, jaundice, weight loss.
EloreMed Editor: Le Wang, MD, PhD Date of Update: 2/6/2018 UpToDate: Liposomal irinotecan (Onivyde) plus FU/LV is now approved for gemcitabine-refractory metastatic pancreatic cancer and recommended by
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationStage III NSCLC: Overview
Locally Advanced NSCLC: New Concepts in Combined Modality Therapy NSCLC: Stage Distribution Randeep Sangha, MD Visiting Assistant Professor UC Davis Cancer Center Sacramento, CA Stage III NSCLC: Overview
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationNEOADJUVANT THERAPY IN CARCINOMA STOMACH. Dr Jyotirup Goswami Consultant Radiation Oncologist Narayana Superspeciality Hospital, Howrah
NEOADJUVANT THERAPY IN CARCINOMA STOMACH Dr Jyotirup Goswami Consultant Radiation Oncologist Narayana Superspeciality Hospital, Howrah NEOADJUVANT THERAPY?! Few believers Limited evidence Many surgeons
More informationNOVITA IN TEMA DI CARCINOMA GASTRICO ROSA BERENATO
NOVITA IN TEMA DI CARCINOMA GASTRICO ROSA BERENATO ONCOLOGIA MEDICA 1 FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI MILANO PROGRESS AGAINST METASTATIC GC OS in first-line palliative setting Little progress
More informationGI Tumor Board 3/8/2018. Case #1 IDEA. Case #1 Question #1 What is the next step in management?
GI Tumor Board Edward Kim George Poultsides Naseem Esteghamat Kenzo Hirose May Cho Alan Venook Arta Monjazeb Margaret Tempero George Fisher Andrew Ko Daniel Chang Thomas Semrad Sisi Haraldsdottir Case
More informationCase Conference. Craig Morgenthal Department of Surgery Long Island College Hospital
Case Conference Craig Morgenthal Department of Surgery Long Island College Hospital Neoadjuvant versus Adjuvant Radiation Therapy in Rectal Carcinoma Epidemiology American Cancer Society statistics for
More informationPancreatic Cancer Where are we?
Pancreatic Cancer Treatment Approaches & Options Pancreatic Cancer Action Network OUMC 9/22/2016 Russell G. Postier, MD Pancreatic Cancer Where are we? Estimated 2016 data 3% of cancer cases 7% of cancer
More informationManagement of advanced Gastric Cancer in the era of targeted therapy
Management of advanced Gastric Cancer in the era of targeted therapy Osman M.Mansour Prof. Medical Oncology, NCI, Cairo University BGO: 28-3 October 215 Gastric Cancer: A Significant Problem in Some Countries
More informationNovel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX
Novel Chemotherapy Agents for Metastatic Breast Cancer Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX New Chemotherapy Agents in Breast Cancer New classes of drugs Epothilones Halichondrin
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Ramucirumab (Cyramza) for Gastric Cancer October 29, 2015
pan-canadian Oncology Drug Review Final Clinical Guidance Report Ramucirumab (Cyramza) for Gastric Cancer October 29, 2015 DISCLAIMER Not a Substitute for Professional Advice This report is primarily intended
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationDr Roopinder Gillmore July 2017
Dr Roopinder Gillmore July 2017 Resectable Borderline / locally advanced Metastatic 15-20% 15-20% 60-70% 22-28 months 9-15 months 6-12 months Does the patient have resectable disease?? Definitely not
More informationState of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan
State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival
More informationWelcome to Master Class for Oncologists. Miami, FL. December 19, The following relationships exist related to this presentation: Session 2
Session 2 Welcome to Master Class for Oncologists 8:15 AM 9:00 AM Miami, FL December 19, 2009 Alan P. Venook, MD Professor of Clinical Medicine University of California San Francisco Medical School Chief,
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationIntended for use by Clinicians and Health Care Providers involved in the Management or Referral of adult patients with pancreatic
Intended for use by Clinicians and Health Care Providers involved in the Management or Referral of adult patients with pancreatic cancer Section AA Cancer Centre Referrals In the absence of metastatic
More informationChemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA
Chemotherapy for resectable liver mets: Options and Issues Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy regimens in 1 st line mcrc Standard FOLFOX-Bev FOLFIRI-Bev
More informationTHE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA. TIMUR MITIN, MD, PhD
THE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA TIMUR MITIN, MD, PhD RESECTABLE DISEASE MANAGEMENT: RESECTABLE DISEASE Resection offers the only possibility of long term survival
More informationRecent Therapeutic Advances for Thoracic Malignancies
Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation
More informationRob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Prague July 2016 State of the art: Standard of care for anal squamous cancer Rob Glynne-Jones Mount Vernon Cancer Centre Aim to discuss Background The trials
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More information